In neuroblastoma, NTRK1 expression is associated with benign clinical features (e.g., young age, favorable pathology and non-MYCN amplified genetic status), tumor cell differentiation and good outcome (Pajtler et al. 2014; Schramm et al. 2012). Here, MYCN is linked to neoplasm.